急诊科非低危改良HEART评分患者的60天主要不良心脏事件
本研究为回顾性队列的二次分析,纳入2013至2015年间因胸痛就诊于整合医疗系统的急诊患者,要求6小时内完成连续肌钙蛋白检测,排除ECG缺血、肌钙蛋白超过第99百分位或缺乏60天连续保险覆盖者。共22976例次符合条件,其中13521例次(59%)改良HEART评分≥4。该组60天MACE(心肌梗死、心脏骤停、心源性休克或死亡)风险为2.0%(95%CI 1.8-2.3),若将全部冠状动脉血运重建纳入(MACE-R)则为4.4%(95%CI 4.1-4.4)。作者认为,排除肌钙蛋白异常或ECG缺血后,非低危改良HEART评分患者的近期MACE风险似乎远低于原始HEART评分验证研究。
要点
- 改良HEART评分≥4且已排除肌钙蛋白异常或ECG缺血的急诊胸痛患者,60天MACE风险为2.0%(95%CI 1.8-2.3)。
- 若将全部冠状动脉血运重建计入复合终点(MACE-R),该组60天风险为4.4%(95%CI 4.1-4.4)。
- 22976例次符合条件中,13521例次(59%)改良HEART评分≥4。
- 作者认为该残余风险似乎远低于原始HEART评分验证研究中的非低危患者。
- 改良HEART评分通过重复肌钙蛋白检测并排除肌钙蛋白异常或ECG缺血患者来提高敏感性。
适用人群与场景
- 2013至2015年间因胸痛就诊于整合医疗系统急诊科的患者。
- 纳入条件:急诊到达6小时内完成连续肌钙蛋白检测。
- 排除:ECG提示缺血、肌钙蛋白超过第99百分位、缺乏覆盖60天随访期的连续保险计划。
诊断标准与关键阈值
- 改良HEART评分:在原始HEART评分基础上重复肌钙蛋白检测,并排除肌钙蛋白异常或ECG缺血患者。
- 非低危定义为改良HEART评分≥4。
- MACE定义:心肌梗死、心脏骤停、心源性休克或死亡的复合终点;MACE-R在此基础上加入全部冠状动脉血运重建。
研究设计与关键结果
- 研究类型:回顾性队列的二次分析;样本量22976例次符合条件,其中13521例次(59%)改良HEART评分≥4。
- 主要终点:非低危改良HEART评分组60天MACE风险2.0%(95%CI 1.8-2.3)。
- 关键次要终点:纳入全部冠状动脉血运重建后(MACE-R),60天风险4.4%(95%CI 4.1-4.4)。
证据类型、等级与局限
- 证据类型:回顾性队列的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,排除肌钙蛋白异常或ECG缺血后,非低危改良HEART评分患者的近期MACE风险似乎远低于原始HEART评分验证研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A low (0-3) History, Electrocardiogram, Age, Risk factors and Troponin (HEART) score reliably identifies ED chest pain patients who are low risk for near-term major adverse cardiac events (MACE). To optimize sensitivity, many clinicians employ a modified HEART score by repeating troponin measurements and excluding patients with abnormal troponin values or ischemic electrocardiograms (ECGs). The residual MACE risk among patients with otherwise non-low (≥4) modified HEART scores is thus likely much lower than with non-low original HEART scores.
OBJECTIVE: To explore residual 60-day MACE risks among patients with non-low modified HEART scores.
METHODS: Secondary analysis of a retrospective cohort of ED patients presenting with chest pain to an integrated healthcare system between 2013 and 2015. Patients with serial troponin measurements within 6 h of ED arrival were considered for inclusion. Exclusions included an ischemic ECG, troponin values above the 99th percentile or a lack of continuous health plan coverage through the 60-day follow-up period. MACE was defined as a composite of myocardial infarction, cardiac arrest, cardiogenic shock or death.
RESULTS: There were 22,976 study eligible patients encounters, 13,521 (59%) of which had non-low (≥4) modified HEART scores. The observed 60-day MACE risk among non-low HEART score patients was 2.0% (95% CI 1.8-2.3). When including all coronary revascularizations (MACE-R), the risk was 4.4% (95% CI 4.1-4.4).
CONCLUSION: Risk of near-term MACE among patients with non-low modified HEART scores (excluding those with abnormal troponin or ischemic ECGs) appears to be much lower than in the original HEART score validation studies.
参考来源
- Mark DG, Huang J, Kennedy CJ, et al. 60-day major adverse cardiac events in emergency department patients with non-low modified HEART scores. Am J Emerg Med. 2020. PMID: 32518023. doi:10.1016/j.ajem.2020.05.081
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。